Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-01-25
2011-01-25
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C536S055100, C536S123000, C536S123100
Reexamination Certificate
active
07875596
ABSTRACT:
Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or 3-O positions of the uronic acid and glucosamine saccharide residues. Particularly effective dermatan sulfate HIT antagonists have a mean molecular weight of from about 2000 to about 10,000 Daltons.
REFERENCES:
patent: 4373023 (1983-02-01), Langer et al.
patent: 4757057 (1988-07-01), Fussi et al.
patent: 4943630 (1990-07-01), Jacquinet
patent: 4987222 (1991-01-01), De Ambrosi et al.
patent: 5100383 (1992-03-01), Lichtenstein
patent: 5262325 (1993-11-01), Zimmermann et al.
patent: 5296471 (1994-03-01), Holme et al.
patent: 5389618 (1995-02-01), Debrie
patent: 5466582 (1995-11-01), Amiral
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5650386 (1997-07-01), Leone-Bay et al.
patent: 5668118 (1997-09-01), Kennedy
patent: 5707974 (1998-01-01), Kennedy
patent: 5808021 (1998-09-01), Holme et al.
patent: 5912237 (1999-06-01), Kennedy
patent: 5922690 (1999-07-01), Van Gorp et al.
patent: 5965121 (1999-10-01), Leone-Bay et al.
patent: 5972717 (1999-10-01), Aster et al.
patent: 5972718 (1999-10-01), Moghaddam et al.
patent: 5990097 (1999-11-01), Kennedy
patent: 5995208 (1999-11-01), Sarge et al.
patent: 6077683 (2000-06-01), Kennedy
patent: 6093563 (2000-07-01), Bennett et al.
patent: 6486137 (2002-11-01), Lundquist et al.
patent: 6518244 (2003-02-01), Cardin et al.
patent: 6579725 (2003-06-01), Seeberger et al.
patent: 6846917 (2005-01-01), Seeberger et al.
patent: 7279177 (2007-10-01), Looney et al.
patent: 7468358 (2008-12-01), Kennedy et al.
patent: 2003/0092671 (2003-05-01), Johansen et al.
patent: 2007/0123489 (2007-05-01), Kennedy et al.
patent: 0040144 (1986-11-01), None
patent: WO 93/05075 (1993-03-01), None
patent: WO 94/09034 (1994-04-01), None
patent: WO 98/55514 (1998-12-01), None
patent: WO 99/38827 (1999-08-01), None
patent: WO 02-20091 (2002-03-01), None
Silverman, “The Organic Chemistry of Drug Design and Drug Action” Published 1992 by Academic Press, chapter 2, pp. 4-47.
Taliani et al., “Dermatan Sulfate in Patients with Heparin-induced Thrombocytopenia” British Journal of Haematology (1999) vol. 104, pp. 87-89.
Tcheng, “Clinical Challenges of Platelet Blycoprotein IIb/IIIa Receptor Inhibitor Therapy: Bleeding, Reversal, Thrombocytopenia, and Retreatment,”Am. Heart J. (2000) 139(2):538-45.
Tollefsen et al., “Modulation of Heparin Cofactor II Activity by Histidine-Rich Glycoprotein and Platelet Factor 4,”J. Clin Invest. (1985) 75:496-501.
Trossaert et al., “High Incidence of Anti-Heparin/Platelet Factor 4 Antibodies After Cardiopulmonary Bypass surgery,”Br. J. Haematol. (1998) 101(4):653-55.
Utley, “Cardiopulmonary Bypass Surgery,”Curr. Opin. Cardiol. (1992) 7(2):267-75.
Vahdat et al, “Fatal Cerebral Hemorrhage and Severe Thrombocytopenia During Abciximab Treatment,”Cath. Cardio. Interv. (2000) 49:177-80.
Van Demem et al., “Determinations of the Molecular Mass of Low Molecular Mass (LMM) Heparin,”Pharmeuropa(1991) 3:202-25.
Visentin et al., “Antibodies from Patients with Heparin-Induced Thrombocytopenia/Thrombosis Are Specific for Platelet Factor 4 Complexed with Heparin or Bound to Endothelial Cells,”J. Clin. Invest. (1994) 93:81-88.
Visentin et al., “Heparin Is not Required for Detection of Antibodies Associated with Heparin-Induced Thrombocytopenia/Thrombosis,”J. Lab. Clin. Med. (2001) 138:22-31.
Walenga et al., “Clinical Experience with Combined Treatment of Thrombin Inhibitors and GPIIb/IIIa Inhibitors in Patients with HIT,”Semin. Thromb. Hemost. (1999) 25(Suppl I): 77-81.
Walenga et al., “Intimatan Ameliorates the Activation of Human Platelets by Heparin/Heparin Antibody from Patients with Heparin-Induced Thrombocytopenia,” Slide of Loyola University Medical Center and Celsus Laboratories, Inc.
Walenga et al., “Combined Thrombin and Platelet Inhibition Treatment for HIT Patients,”Hämostaseologie(1999) 19:128-33.
Walenga et al., “Laboratory Tests for the Diagnosis of Heparin-Induced Thrombocytopenia,”Semin. Thromb. Hemost. (1999) 25 (Suppl 1): 43-49.
Wallis et al., “Failure of Early Heparin Cessation as Treatment for Heparin-Induced Thrombocytopenia,”Am. J. Med. (1999) 106(6): 629-635.
Warkentin et al, “Temporal Aspects of Heparin-Induced Thrombocytopenia,”N. Eng. J. Med. (2001) 344:1286-1292.
Warkentin et al., “A 14-Year Study of Heparin-Induced Thrombocytopenia,”Am. J. Med. (1996) 101:502-507.
Xuchong et al., “Generation of Anti-Hirudin Antibodies in Heparin-Induced Thrombocytopenic Patients Treated with R-Hirudin,” Circulation (1999) 1528-32.
Yang et al., “Intimatan, A Heparin Cofactor II Catalyst, Inhibits Vessel Wall Thrombogenicity and Intimal Hyperplasia More Effectively than Heparin,” 1311:414.
Zhasng et al., “Crystal Structure of Recombinant Hum Platelet Factor 4,”Biocemistry(1994) 33:8361-66.
Merriam-Webster's Collegiate Dictionary, Tenth Edition, published 1998 by Merriam-Webster, Incorporated, p. 924.
Van Dedem, et al. “Determinations of the Molecular Mass of Low Molecular Mass (LMM) Heparin”Pharmaeuropa, vol. 3, No. 3, (Oct. 1991), pp. 202-218.
Taube, et al., “Inhibition of Complement Activation Decreases Airway Inflammation and Hyperresponsiveness” American Journal of Respiratory and Critical Care Medicine (2003), vol. 168, pp. 1333-1341.
Blain, et al., “Expression System for High Levels of GAG Lyase Gene Expression and Study of the heap Upstream Region inFlavobacterium heparinum” Journal of Bacteriology (2002), vol. 184, pp. 3242-3252/.
Bar-Shavit et al., “Binding of Thrombin to Subendothelial Extracellular Matrix,”J. Clin Invest. (1989) 84:1096-1104.
Bauer et al., “Prevalence of Heparin-Associated Antibodies without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery,”Circulation(1997)95:1242-46.
Blank et al., “Anti-Platelet Factor 4/Heparin Antibodies from Patients with Heparin-Induced Thrombocytopenia Provoke Direct Activation of Microvascular Endothelial Cells,”Int. Immunol. (2002) 14:121-29.
Bock et al., “The Multiple Complexes Formed by the Interaction of Platelet Factor 4 with Heparin,”Biochem. J. (1980) 191:709-10.
Brandjes et al., “Acenocoumarol and Heparin Compared with Acenocoumarol Alone in the Initial Treatment of Proximal-Vein Thrombosis,”N. Engl. J. Med. (1992) 327(21): 1485-89.
Brieger et al., “Heparin-Induced Thrombocytopenia,”J. Am. Coll. Cardiol. (1998) 31:1449-1459.
Charles et al., “The Three Dimensional structure of Bovine Platelet Factor 4 at 3.0 Å Resolution,”J. Biol. Chem. (1989) 264:2092-99.
Fahey, “Heparin-Induced Thrombocytopenia.”J. Vasc. Nurs. (1995) 13:112-116; http://www.argatroban.com/ref 0.1 htm, 2004.
Goad et al., “Pentosan-Induced Thrombocytopenia: Support for an Immune Complex Mechanism,”Brit. J. Haematol. (1994) 88:803-08.
Greinacher et al., “Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-Associated Thrombocytopenia,”Thromb. Haemost. (1995) 74:886-892.
Greinacher et al., “Heparin-Associated Thrombocytopenia in a Patient Treated with Polysulphated Chondroitin Sulphate: Evidence for Immunological Crossreactivity between Heparin and Polysulphated Glycosaminoglycan,”Brit. J. Haematol. (1992) 81: 252-54.
Greinacher et al., “Heparin-Associated Thrombocytopenia: Isolation
Celsus Biopharmaceuticals, Inc.
Eric W. Guttag IP Law Office
Guttag Eric W.
Olson Eric S
LandOfFree
Use of dermatan sulfates and/or desulfated heparins to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of dermatan sulfates and/or desulfated heparins to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dermatan sulfates and/or desulfated heparins to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2647344